Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.

Potential Commercial Applications: Competitive Advantages:
  • Novel anthrax vaccines
  • Post-vaccination screening to determine if anthrax protection is achieved
  • Biodefense
  • May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
  • Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.

Development Stage:
  • Pre-clinical
  • In vitro data available


Vera Semenova (CDC)  ➽ more inventions...

Conrad Quinn (CDC)  ➽ more inventions...

Jan Pohl (CDC)  ➽ more inventions...

Pavel Svoboda (CDC)  ➽ more inventions...

Shannon Dalton (CDC)  ➽ more inventions...

Jarad Schiffer (CDC)  ➽ more inventions...

Stephen Soroka (CDC)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,046,520 issued 2015-06-02
U.S. Pat: 9,102,742 issued 2015-08-11
U.S. Pat: 9,610,338 issued 2017-04-04
U.S. Pat: 9,782,465 issued 2017-10-10
US Application No. 14/669,580
US Application No. 15/438,152

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Phone: 301-594-9719

OTT Reference No: E-158-2013-2
Updated: Jan 14, 2016